Efficacy of Infliximab for Early Remission Induction in Refractory Uveoretinitis Associated with Behçet Disease: A 2-year Follow-up Study
Author:
Affiliation:
1. Department of Ophthalmology, Kyorin University School of Medicine, Tokyo, Japan
2. Department of Ophthalmology, Toyama University School of Medicine, Toyama, Japan
Funder
Mitsubishi Tanabe Pharma
Publisher
Informa UK Limited
Subject
Ophthalmology,Immunology and Allergy
Link
https://www.tandfonline.com/doi/pdf/10.1080/09273948.2016.1239746
Reference23 articles.
1. Current Concepts in the Etiology and Treatment of Behçet Disease
2. A Major Review: Current Aspects of Ocular Behçet's Disease in Japan
3. Risk and prognostic factors of poor visual outcome in Behcet's disease with ocular involvement
4. Best-corrected visual acuity and frequency of ocular attacks during the initial 10 years in patients with Behçet’s disease
Cited by 29 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Behçet disease: epidemiology, classification criteria and treatment modalities;Expert Review of Clinical Immunology;2024-08-11
2. Early versus late initiation of infliximab for refractory uveitis in a cohort of Egyptian BD patients;Journal of the Egyptian Ophthalmological Society;2024-07
3. Advances in pathogenesis and treatment of ocular involvement in Behcet’s disease;Frontiers in Immunology;2023-09-29
4. Biologic therapy in large and small vessels vasculitis, and Behçet’s disease: Evidence- and practice-based guidance;Autoimmunity Reviews;2023-08
5. Comparing biologic options for the management of Behcet’s disease-related uveitis;Expert Review of Clinical Immunology;2023-02-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3